Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Rectal Cancer

Clinical Trial at: Compass Oncology - Vancouver

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

  • Details

ClinicalTrials.gov ID: NCT04813627
Diagnosis Type: Rectal Cancer
USOR Number: 21385

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Rectal Cancer

Clinical Trial at: Compass Oncology - Portland

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

  • Details

ClinicalTrials.gov ID: NCT04813627
Diagnosis Type: Rectal Cancer
USOR Number: 21385

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Rectal Cancer

Clinical Trial at: Compass Oncology - Portland

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

  • Details

ClinicalTrials.gov ID: NCT04813627
Diagnosis Type: Rectal Cancer
USOR Number: 21385

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page

Rectal Cancer

Clinical Trial at: Compass Oncology - Tigard

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001)

  • Details

ClinicalTrials.gov ID: NCT04813627
Diagnosis Type: Rectal Cancer
USOR Number: 21385

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708.7600

More Details View Practice Page

Solid Tumors

Clinical Trial at: Compass Oncology - Tigard

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

  • Details

ClinicalTrials.gov ID: NCT04383210
Diagnosis Type: Solid Tumors
USOR Number: 20245

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708.7600

More Details View Practice Page

Solid Tumors

Clinical Trial at: Compass Oncology - Vancouver

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

  • Details

ClinicalTrials.gov ID: NCT04383210
Diagnosis Type: Solid Tumors
USOR Number: 20245

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page

Solid Tumors

Clinical Trial at: Compass Oncology - Portland

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

  • Details

ClinicalTrials.gov ID: NCT04383210
Diagnosis Type: Solid Tumors
USOR Number: 20245

  • Practice Details

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

More Details View Practice Page

Solid Tumors

Clinical Trial at: Compass Oncology - Portland

CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

  • Details

ClinicalTrials.gov ID: NCT04383210
Diagnosis Type: Solid Tumors
USOR Number: 20245

  • Practice Details

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

More Details View Practice Page

Solid Tumors

Clinical Trial at: Compass Oncology - Tigard

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

  • Details

ClinicalTrials.gov ID: NCT05103358
Diagnosis Type: Solid Tumors
USOR Number: 22052

  • Practice Details

12123 SW 69th Avenue
Tigard, OR 97223
P: (971) 708.7600

More Details View Practice Page

Solid Tumors

Clinical Trial at: Compass Oncology - Vancouver

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)

  • Details

ClinicalTrials.gov ID: NCT05103358
Diagnosis Type: Solid Tumors
USOR Number: 22052

  • Practice Details

210 SE 136th Ave
Vancouver, WA 98684
P: (360) 944-9889

More Details View Practice Page
1 2 3 18